Publications by authors named "Allan Olson"

Claim this Profile
E
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
Silvio Danese, Barrett G Levesque, Brian G Feagan, Alina Jucov, B R Bhandari, Allan Olson

Aliment Pharmacol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis.
Silvio Danese, Barrett G Levesque, Brian G Feagan, Alina Jucov, Bal Raj Bhandari, Allan Olson

Aliment Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Brian G Feagan, William J Sandborn, Silvio Danese, Douglas C Wolf, Wenzhong J Liu, Allan Olson

Lancet Gastroenterol Hepatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can diabetes be cured?
Allan Olson

J Fam Pract· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.
Vipul Jairath, Laurent Peyrin-Biroulet, Guangyong Zou, Mahmoud Mosli, Niels Vande Casteele, Allan Olson

Gut· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Ikuo Hirano, Margaret H Collins, Yehudith Assouline-Dayan, Larry Evans, Sandeep Gupta, Allan Olson

Gastroenterology· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.
Vipul Jairath, Jenny Jeyarajah, Guangyong Zou, Claire E Parker, Allan Olson

Lancet Gastroenterol Hepatol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
Jonathan Q Tran, Jeffrey P Hartung, Allan D Olson, Boaz Mendzelevski, Gregg A Timony

Clin Pharmacol Drug Dev· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
Jonathan Q Tran, Jeffrey P Hartung, Robert J Peach, Marcus F Boehm, Hugh Rosen, Allan D Olson

J Clin Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
William J Sandborn, Brian G Feagan, Douglas C Wolf, Geert D'Haens, Severine Vermeire, Allan Olson

N Engl J Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Jeffrey A Cohen, Douglas L Arnold, Giancarlo Comi, Amit Bar-Or, Sheila Gujrathi, Allan Olson

Lancet Neurol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.
Mihai Gheorghiade, Stephen J Greene, Piotr Ponikowski, Aldo P Maggioni, Jerzy Korewicki, Allan Olson

Eur J Heart Fail· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
William J Sandborn, Paul Rutgeerts, Brian G Feagan, Walter Reinisch, Allan Olson

Gastroenterology· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.
Wallace Crandall, Jeffrey Hyams, Subra Kugathasan, Anne Griffiths, Julie Zrubek, Allan Olson

J Pediatr Gastroenterol Nutr· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Meena Thayu, Mary B Leonard, Jeffrey S Hyams, Wallace V Crandall, Subra Kugathasan, Allan Olson

Clin Gastroenterol Hepatol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
Walter Reinisch, William J Sandborn, Mohan Bala, Songkai Yan, Brian G Feagan, Allan Olson

Inflamm Bowel Dis· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Brian G Feagan, Walter Reinisch, Paul Rutgeerts, William J Sandborn, Songkai Yan, Allan Olson

Am J Gastroenterol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Jeffrey Hyams, Wallace Crandall, Subra Kugathasan, Anne Griffiths, Allan Olson

Gastroenterology· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.
Edouard J Louis, Hervé E Watier, Stefan Schreiber, Jochen Hampe, François Taillard, Allan Olson

Pharmacogenet Genomics· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Gary R Lichtenstein, Allan Olson, Suzanne Travers, Robert H Diamond, Donny M Chen

Am J Gastroenterol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Paul Rutgeerts, Robert H Diamond, Mohan Bala, Allan Olson, Gary R Lichtenstein

Gastrointest Endosc· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts, William J Sandborn, Brian G Feagan, Walter Reinisch, Allan Olson

N Engl J Med· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
Karel Geboes, Paul Rutgeerts, Ghislain Opdenakker, Allan Olson, Kamlesh Patel

Curr Med Res Opin· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unemployment and disability in patients with moderately to severely active Crohn's disease.
Brian G Feagan, Mohan Bala, Songkai Yan, Allan Olson, Stephen Hanauer

J Clin Gastroenterol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
Stephen B Hanauer, Carrie L Wagner, Mohan Bala, Lloyd Mayer, Suzanne Travers, Allan Olson

Clin Gastroenterol Hepatol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis